Xeris Biopharma Holdings (XERS) EBIT Growth (1y) (2021 - 2026)
Xeris Biopharma Holdings (XERS) EBIT Growth (1y) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn | 25.63% |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn | -1.30% |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn | -14.89% |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn | -46.83% |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn | 719.49% |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn | 23.29% |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn | -450.06% |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn | -235.28% |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn | -20.32% |
| 10 | Xeris Biopharma Holdings | 1.11 Bn | 994.95 Mn | 72.55 Mn | 356.18% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 356.18% |
| Dec 31, 2025 | 898.99% |
| Sep 30, 2025 | 152.21% |
| Jun 30, 2025 | 154.75% |
| Mar 31, 2025 | 78.31% |
| Dec 31, 2024 | 117.06% |
| Sep 30, 2024 | -162.43% |
| Jun 30, 2024 | 48.76% |
| Mar 31, 2024 | -7.29% |
| Dec 31, 2023 | 35.13% |
| Sep 30, 2023 | 73.84% |
| Jun 30, 2023 | 15.53% |
| Mar 31, 2023 | 54.33% |
| Dec 31, 2022 | 68.57% |
| Sep 30, 2022 | 22.90% |
| Jun 30, 2022 | 26.65% |
| Mar 31, 2022 | -73.68% |
| Dec 31, 2021 | -149.55% |
| Sep 30, 2021 | -77.23% |